Screener
TG Therapeutics TGTX Equity Method Investments
Equity Method Investments at other companies
Other financials
Where this comes from
Reported directly by TG Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:LongTermInvestments.
The source filing: TG Therapeutics’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 5:01 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001437749-26-025955
| Line item | June 30, 2026 | December 31, 2025 |
|---|---|---|
| Other current assets | 43,901 | 57,580 |
| Total current assets | 1,145,687 | 630,764 |
| Restricted cash | 1,364 | 1,342 |
| Long-term investment securities | 64,368 | 59,136 |
| Right of use assets | 7,085 | 6,278 |
| Deferred tax assets | 343,428 | 348,000 |
| Non-current inventories | 75,486 | 15,689 |
| Other noncurrent assets | 2,211 | 2,044 |
Document
FAQ
- What is TG Therapeutics's equity method investments?
- TG Therapeutics (TGTX) reported equity method investments of $64.37M in Q2 2026.
- How has TG Therapeutics's equity method investments changed year-over-year?
- TG Therapeutics's equity method investments increased by 125.1% year-over-year, from $28.59M to $64.37M.
- What is the long-term trend for TG Therapeutics's equity method investments?
- Over 4 years (2021 to 2025), TG Therapeutics's equity method investments has grown at a 13.6% compound annual growth rate (CAGR), from $35.53M to $59.14M.
- What does equity method investments mean?
- Investments in unconsolidated affiliates and joint ventures where the company has significant influence (typically 20-50% ownership), carried at proportional book value.
Ask your AI about TG Therapeutics's equity method investments.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude